← Lantheus overview

Lantheus vs Opko Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Lantheus Holdings Inc (LNTH)

Q3 2026
▲2▼1

Curium's $8B buyout and new FDA approval reshape Lantheus

  • Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.

    The buyout is the single biggest force driving LNTH's price and future value.

  • FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.

    A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.

  • FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.

    This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.

July 2026
▲2▼1

Curium's $8B buyout and new FDA approval reshape Lantheus

  • Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.

    The buyout is the single biggest force driving LNTH's price and future value.

  • FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.

    A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.

  • FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.

    This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.

Latest
▲2▼1

Curium's $8B buyout and new FDA approval reshape Lantheus

  • Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.

    The buyout is the single biggest force driving LNTH's price and future value.

  • FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.

    A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.

  • FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.

    This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.

Opko Health Inc (OPK)

Q3 2026
▲4

OPKO's Q2 Beat, Raised Guidance, and Royalty-Backed Cash Drive Gains

  • Q2 beat and raised 2026 revenue guidance OPKO reported Q2 revenue of $163.6 million, beating estimates, and raised full-year 2026 revenue guidance to $560–$585 million. The net loss narrowed to a penny a share from a huge loss a year earlier. This tells investors the business is stabilizing and growing, which pushes the stock up.

    This is the core new financial event that directly lifted the stock and improved the outlook.

  • Pipeline progress and new CAR-T trial planned OPKO's ModeX platform is advancing multiple candidates, including BARDA-funded MDX2301, and the company plans first-in-human trials for its in vivo CAR-T asset MDX3001 by late 2026 or early 2027. New pipeline milestones give investors hope for future revenue beyond current products.

    Pipeline advancement is a key reason investors are willing to look past current losses and bid the stock higher.

  • $125 million royalty-backed financing without dilution OPKO raised $125 million by issuing notes secured by its mazdutide royalty stream from Eli Lilly. This gives fresh cash without selling new shares, so existing investors are not diluted. The money can fund operations and pipeline trials, reducing financial risk and supporting the stock.

    This new financing strengthens the balance sheet and is a direct positive for the stock.

  • Narrower losses and improved margins at BioReference OPKO's Q2 operating loss shrank to $7 million from $60 million a year earlier, and gross margin jumped to 48.9% from 31.5%. BioReference swung to a $4.8 million operating profit from a big loss, helped by cost cuts and an earnout gain. Better profitability supports the stock.

    This explains the fundamental improvement that has driven the recent share price gain.

August 2026
▲4

OPKO's Q2 Beat, Raised Guidance, and Royalty-Backed Cash Drive Gains

  • Q2 beat and raised 2026 revenue guidance OPKO reported Q2 revenue of $163.6 million, beating estimates, and raised full-year 2026 revenue guidance to $560–$585 million. The net loss narrowed to a penny a share from a huge loss a year earlier. This tells investors the business is stabilizing and growing, which pushes the stock up.

    This is the core new financial event that directly lifted the stock and improved the outlook.

  • Pipeline progress and new CAR-T trial planned OPKO's ModeX platform is advancing multiple candidates, including BARDA-funded MDX2301, and the company plans first-in-human trials for its in vivo CAR-T asset MDX3001 by late 2026 or early 2027. New pipeline milestones give investors hope for future revenue beyond current products.

    Pipeline advancement is a key reason investors are willing to look past current losses and bid the stock higher.

  • $125 million royalty-backed financing without dilution OPKO raised $125 million by issuing notes secured by its mazdutide royalty stream from Eli Lilly. This gives fresh cash without selling new shares, so existing investors are not diluted. The money can fund operations and pipeline trials, reducing financial risk and supporting the stock.

    This new financing strengthens the balance sheet and is a direct positive for the stock.

  • Narrower losses and improved margins at BioReference OPKO's Q2 operating loss shrank to $7 million from $60 million a year earlier, and gross margin jumped to 48.9% from 31.5%. BioReference swung to a $4.8 million operating profit from a big loss, helped by cost cuts and an earnout gain. Better profitability supports the stock.

    This explains the fundamental improvement that has driven the recent share price gain.

Latest
▲4

OPKO's Q2 Beat, Raised Guidance, and Royalty-Backed Cash Drive Gains

  • Q2 beat and raised 2026 revenue guidance OPKO reported Q2 revenue of $163.6 million, beating estimates, and raised full-year 2026 revenue guidance to $560–$585 million. The net loss narrowed to a penny a share from a huge loss a year earlier. This tells investors the business is stabilizing and growing, which pushes the stock up.

    This is the core new financial event that directly lifted the stock and improved the outlook.

  • Pipeline progress and new CAR-T trial planned OPKO's ModeX platform is advancing multiple candidates, including BARDA-funded MDX2301, and the company plans first-in-human trials for its in vivo CAR-T asset MDX3001 by late 2026 or early 2027. New pipeline milestones give investors hope for future revenue beyond current products.

    Pipeline advancement is a key reason investors are willing to look past current losses and bid the stock higher.

  • $125 million royalty-backed financing without dilution OPKO raised $125 million by issuing notes secured by its mazdutide royalty stream from Eli Lilly. This gives fresh cash without selling new shares, so existing investors are not diluted. The money can fund operations and pipeline trials, reducing financial risk and supporting the stock.

    This new financing strengthens the balance sheet and is a direct positive for the stock.

  • Narrower losses and improved margins at BioReference OPKO's Q2 operating loss shrank to $7 million from $60 million a year earlier, and gross margin jumped to 48.9% from 31.5%. BioReference swung to a $4.8 million operating profit from a big loss, helped by cost cuts and an earnout gain. Better profitability supports the stock.

    This explains the fundamental improvement that has driven the recent share price gain.